Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of [14c]-Samidorphan in Healthy Males
NCT02504463Phase 1Completed
- Sponsor
- Alkermes
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of samidorphan in major depressive disorder (MDD) (3 arms), sponsored by Alkermes. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration, Maximum Plasma Concentration and 2 more. Started Jun 2015; status: completed.
02
Drugs
samidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02504463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504463.